Protocol Ledger

NCT06790784 · Phase III · RECRUITING

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Interventional Phase III clinical trial protocol NCT06790784 sponsored by Jaeb Center for Health Research in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-04 Enrollment: 426 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06790784
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)426 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06790784
Protocol FieldVerified Registry Value
NCT IdentifierNCT06790784
Consolidated Lead SponsorJaeb Center for Health Research
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment426 participants (ESTIMATED)
Registered Start Date2025-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06790784
Hospital Research SiteLocationSite Profile
Loma Linda University Medical CenterLoma Linda, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI